Marc Semigran, MD is an Associate Professor of Medicine at Harvard Medical School. He has served as Medical Director of the Massachusetts General Hospital Heart Failure and Cardiac Transplant Program. He is a graduate of the Harvard/Massachusetts Institute of Technology Health Sciences and Technology Program. He completed his internal medicine residency and cardiology fellowship training at Mass General.

Dr. Semigran’s major research interest is in the role of right ventricular function in the pathophysiology of heart failure and in cardiac and vascular NO/cGMP signal transduction. He has authored numerous publications on the treatment of pulmonary hypertension and congestive heart failure.

Dr. Semigran is a recipient of National Institutes of Health and industry research awards for this work, and he leads the National Heart, Lung and Blood Institute Heart Failure Network Regional Clinical Center at Harvard. He is the Principal Investigator of an NHLBI-sponsored multicenter trial of type 5 phosphodiesterase inhibition for the treatment of heart failure.

Dr. Semigran also has a long-standing interest in innovative approaches to amyloid heart disease including cardiac and stem-cell transplantation, and chairs the International Consortium for Cardiac Amyloid Transplantation.